Previous Close | 17.86 |
1-Year Change | 216.11% |
6-Months Change | 172.26% |
3-Months Change | 108.4% |
Moving Avg (50d) | 16.564 |
Moving Avg (200d) | 10.11 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.34B |
Beta (3-Years) | 1.1 |
Revenue Growth (ttm) | -31.1% |
Net Profit Margin (ttm) | -67.21% |
Return On Assets (ttm) | -10.45% |
EPS (ttm) | -1.46 |
PE Ratio (ttm) | -12.23 |
Dividend Yield | % |
Asset Description: | Travere Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
18.217 | 18.753 | 19.11 | 19.646 | 20.539 | 21.432 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |